Clinical Impact of Follow-Up Endomyocardial Biopsy in Myocarditis During or After Immune-Suppressive Therapy
One-fourth of EMB-proven myocarditis patients had a clinical indication to repeat EMB at least once during long-term follow-up. Follow-up EMB was safe in all cases; it showed active or borderline myocarditis in 55% of patients and lead to a change in management in the majority of patients.
Authors
- Elisa Carturan
- R Marcolongo (ORCID: https://orcid.org/0000-0002-5306-1785)
- Andrea Silvio Giordani (ORCID: https://orcid.org/0000-0002-1525-077X)
- Sabino Iliceto (ORCID: https://orcid.org/0000-0002-3676-8746)
- Alida L.P. Caforio (ORCID: https://orcid.org/0000-0002-4901-5655)
- Cristina Vicenzetto (ORCID: https://orcid.org/0000-0002-2548-4596)
- Federico Scognamiglio (ORCID: https://orcid.org/0000-0002-4610-0950)
- Giuseppe Toscano (ORCID: https://orcid.org/0000-0003-1423-7060)
- Cristina Basso (ORCID: https://orcid.org/0000-0002-0195-9753)
- Monica De Gaspari (ORCID: https://orcid.org/0000-0001-9528-4883)
- Anna Baritussio (ORCID: https://orcid.org/0000-0002-6900-6705)
- Giuseppe Tarantini
Institutions
- University of Padua (IT)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1002/ehf2.15349
- Primary Topic
- Viral Infections and Immunology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00